BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 20816039)

  • 21. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
    Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
    J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
    Kamijima K; Higuchi T; Ishigooka J; Ohmori T; Ozaki N; Kanba S; Kinoshita T; Koyama T;
    J Affect Disord; 2013 Dec; 151(3):899-905. PubMed ID: 24074484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
    J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
    Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
    Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
    Tourian KA; Padmanabhan K; Groark J; Ninan PT
    J Clin Psychopharmacol; 2010 Aug; 30(4):411-6. PubMed ID: 20631558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
    Nelson JC; Rahman Z; Laubmeier KK; Eudicone JM; McQuade RD; Berman RM; Marcus RN; Baker RA; Sheehan JJ
    CNS Spectr; 2014 Dec; 19(6):528-34. PubMed ID: 24642260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies.
    Fava M; Dording CM; Baker RA; Mankoski R; Tran QV; Forbes RA; Eudicone JM; Owen R; Berman RM
    Prim Care Companion CNS Disord; 2011; 13(1):. PubMed ID: 21731833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
    Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
    Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies.
    Weisler R; Montgomery SA; Earley WR; Szamosi J; Eriksson H
    J Clin Psychiatry; 2014 May; 75(5):520-7. PubMed ID: 24816198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
    Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
    Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
    Fava M; Wisniewski SR; Thase ME; Baker RA; Tran QV; Pikalov A; Yang H; Marcus RN; Berman RM
    J Clin Psychopharmacol; 2009 Aug; 29(4):362-7. PubMed ID: 19593176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder.
    Findling RL; Youngstrom EA; McNamara NK; Stansbrey RJ; Wynbrandt JL; Adegbite C; Rowles BM; Demeter CA; Frazier TW; Calabrese JR
    J Clin Psychiatry; 2012 Jan; 73(1):57-63. PubMed ID: 22152402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms.
    Thase ME; Bowden CL; Nashat M; Eudicone JM; Marcus R; McQuade RD; Carlson BX
    Int J Psychiatry Clin Pract; 2012 Jun; 16(2):121-31. PubMed ID: 22296512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Boulton DW; Balch AH; Royzman K; Patel CG; Berman RM; Mallikaarjun S; Reeves RA
    J Psychopharmacol; 2010 Apr; 24(4):537-46. PubMed ID: 18832427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.